Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center and professor of oncologic sciences at University of South Florida, discussed the shift to targeted therapies in acute myeloid leukemia (AML).
The development of targeted therapies are powering a change in the treatment of acute myeloid leukemia (AML), said Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center and professor of oncologic sciences at University of South Florida.
Transcript
How has the landscape of AML treatment evolved in recent years, and what are the implications for managed care decision making?
Well, the landscape has definitely changed gradually, over time with the advent of lower intensity based therapies that have risen to standard of care for older, less fit patients. But perhaps more importantly, the development of targeted therapies that are felt to really change the overall outcome of these patients. Targeted therapies, again, FLT3 inhibitors, IDH inhibitors, and BCL2 inhibitors—like venetoclax—are, I think, at the forefront of the landscape of therapy changing, and we have a variety of new, exciting targeted types of drugs, immunotherapy drugs that are still somewhat in the pipeline, that are showing promise in early phase studies, and will eventually work their way into frontline therapy and become standard of care in that setting.
I think the impact of these therapies on cost and reimbursement is certainly something we have to be paying a lot of attention to, because these new drugs are expensive, and many of them can be given for a long time—perhaps months up to a few years. The traditional high cost of care in AML is related to hospital-based stays and the cost incurred with hospitalizations. As many of these newer treatments, especially the azanucleoside combinations with venetoclax or other targeted agents, are primarily outpatient based, that helps defray hospital costs—but on the other end of the scale, adds cost to pharmacy and outpatient related costs that may go on for a long time if the patient is responding and doing well.
Although it's fantastic that we're seeing new developments in leukemia, and new drugs that are helping patients live longer and live better, there certainly are cost concerns in the long term for these are these drugs that are very expensive and often require a lot of supportive care to go along with them to help maintain patient's quality of life—whether it's transfusion support in the short term, antibiotics, frequent visits, laboratory monitoring, those types of things.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More